Archives
Ivosidenib is approved by FDA for myelodysplastic syndromes
November 24th, 2023 MDSNov 2023: The Food and Drug Administration (FDA) approved Ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) in November 2023 for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes (MDS) who have a suscepti.... Read More
Neoadjuvant/ adjuvant pembrolizumab is approved by the FDA for resectable non-small cell lung cancer
November 24th, 2023 Lung cancerNov 2023: Pembrolizumab (Keytruda, Merck) was granted approval by the Food and Drug Administration (FDA) as a neoadjuvant treatment in combination with platinum-containing chemotherapy and as a post-surgical adjuvant treatment for resectable no.... Read More
Nivolumab is approved by the FDA for adjuvant treatment of Stage IIB/C melanoma
November 24th, 2023 MelanomaNov 2023: Nivolumab (Opdivo, Bristol-Myers Squibb Company) was granted approval by the Food and Drug Administration as an adjuvant therapy for Stage IIB/C melanoma in patients 12 years and older who had undergone complete resection. In the r.... Read More
Encorafenib with binimetinib is approved by the FDA for treatment of metastatic non-small cell lung cancer with a BRAF V600E mutation
November 24th, 2023 Lung cancerThe Food and Drug Administration (FDA) approved Encorafenib (Braftovi, Array BioPharma Inc., a wholly owned subsidiary of Pfizer) and binimetinib (Mektovi, Array BioPharma Inc.) in November 2023 as medicines that can be used to treat adults wit.... Read More
Bosutinib is approved by the FDA for pediatric patients with chronic myelogenous leukemia
November 23rd, 2023 Blood cancerNov 2023: For paediatric patients aged one year and above with chronic phase (CP) Ph+ chronic myelogenous leukaemia (CML), either newly diagnosed (ND) or resistant or intolerant (R/I) to previous therapy, the Food and Drug Administration has ap.... Read More
New and updated indications are approved by FDA for temozolomide under Project Renewal
November 23rd, 2023 CancerNov 2023: Under Project Renewal, an Oncology Centre of Excellence (OCE) initiative aimed at updating labelling information for older oncology drugs to ensure information is clinically meaningful and scientifically up-to-date, the Food and Drug .... Read More
Melphalan is approved by FDA as a liver-directed treatment for uveal melanoma
November 23rd, 2023 Liver cancerNov 2023: The Food and Drug Administration approved HEPZATO KIT (melphalan for Injection/Hepatic Delivery System, Delcath Systems, Inc.) as a liver-directed treatment for adult patients with uveal melanoma who have unresectable hepatic metastas.... Read More
Elranatamab-bcmm receives accelerated approval by FDA for multiple myeloma
November 23rd, 2023 MyelomaNov 2023: Elranatamab-bcmm (Elrexfio, Pfizer, Inc.) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager that was given accelerated approval by the Food and Drug Administration for adults with relapsed or refractory mult.... Read More
How Does CAR T Therapy Works And Transforming Cancer Treatment?
November 18th, 2023 Blood cancer, Cancer treatment in India, Leukemia, LymphomaDiscover the science behind CAR T Cell therapy treatment in India! Explore how this revolutionary treatment transforms your immune cells into cancer fighters. Read our blog now to learn more about this miraculous therapy and how it can help can.... Read More
Is CAR T-Cell Therapy Available In India?
November 18th, 2023 Cancer, Cancer treatment in India, Leukemia, Lymphoma, UncategorizedHave you ever wondered if there is a powerful way to fight cancer? Now just imagine if one day you found a ray of hope in your fight against cancer, a treatment that uses the power of your body's own immune system to target and destroy cance.... Read More
